How to buy Merck-and-Company (MRK) stocks

Merck-and-Company is a drug manufacturers - general business based in the US. Merck-and-Company shares (MRK) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $76.06 , which is a decrease of 5.43% over the previous week. Merck-and-Company employs 73,000 staff and has a trailing 12-month revenue of around $63.9 billion.

Our top picks for where to buy Merck-and-Company stock

Buy Merck-and-Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Merck-and-Company stock price (NYSE: MRK)

Use our graph to track the performance of MRK stocks over time.

Merck-and-Company stocks at a glance

• Key figures

Information last updated 2025-05-15.

Latest market close	$76.06
52-week range	$73.31 - $131.54
50-day moving average more info button	$84.75
200-day moving average more info button	$99.23
Wall St. target price	$102.71
PE ratio more info button	10.6857
Dividend yield more info button	$3.12 (4.41%)
Earnings per share (TTM) more info button	$7.00

Is it a good time to buy Merck-and-Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Merck-and-Company stock undervalued or overvalued?

Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merck-and-Company's P/E ratio

Merck-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Merck-and-Company shares trade at around 11x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.

Merck-and-Company's PEG ratio

Merck-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6858. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Merck-and-Company's EBITDA

Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $28.8 billion.

The EBITDA is a measure of a Merck-and-Company's overall financial performance and is widely used to measure a its profitability.

Merck-and-Company financials

Revenue TTM	$63.9 billion
Operating margin TTM	40.06%
Gross profit TTM	$49.3 billion
Return on assets TTM	13.81%
Return on equity TTM	39.29%
Profit margin	27.27%
Book value	$19.21
Market Capitalization more info button	$187.8 billion

TTM: trailing 12 months

Merck-and-Company stock dividends

Dividend payout ratio: 40.56% of net profits

Recently Merck-and-Company has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $3.12 per share.

While Merck-and-Company's payout ratio might seem fairly standard, it's worth remembering that Merck-and-Company may be investing much of the rest of its net profits in future growth.

Merck-and-Company's most recent dividend payout was on 6 April 2025. The latest dividend was paid out to all shareholders who bought their stocks by 16 March 2025 (the "ex-dividend date").

Have Merck-and-Company's stocks ever split?

Merck-and-Company's stocks were split on a 1048:1000 basis on 2 June 2021 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company stocks – just the quantity. However, indirectly, the new 4.6% lower stock price could have impacted the market appetite for Merck-and-Company stocks, which in turn could have impacted Merck-and-Company's stock price.

Merck-and-Company stock price volatility

Over the last 12 months, Merck-and-Company's stocks have ranged in value from as little as $73.31 up to $131.5369. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-Company's is 0.441. This would suggest that Merck-and-Company's stocks are less volatile than average (for this exchange).

Merck-and-Company overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Merck-and-Company is owned by insiders or institutions?
Currently 0.064% of Merck-and-Company stocks are held by insiders and 81.23% by institutions. How many people work for Merck-and-Company?
Latest data suggests 73,000 work at Merck-and-Company. When does the fiscal year end for Merck-and-Company?
Merck-and-Company's fiscal year ends in December. Where is Merck-and-Company based?
Merck-and-Company's address is: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 What is Merck-and-Company's ISIN number?
Merck-and-Company's international securities identification number is: US58933Y1055 What is Merck-and-Company's CUSIP number?
Merck-and-Company's Committee on Uniform Securities Identification Procedures number is: 589339209

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.